Sis-25, a meroditerpenoid derivative with a cyclobutane scaffold, inhibits activated T cell proliferation by targeting GSK3β in vitro and in vivo

Eur J Pharmacol. 2022 Aug 15:929:175151. doi: 10.1016/j.ejphar.2022.175151. Epub 2022 Jul 13.

Abstract

A series of novel scopariusicide derivatives were designed and synthesized starting from the main diterpenoid from the aerial parts of Isodon scoparius. Sis-25 was the most effective compound among them. The potential mechanism(s) of its immunosuppressive activity in vitro, as well as its effects on delayed type hypersensitivity (DTH) reaction and imiquimod-induced dermatitis in vivo were investigated in this study. Sis-25 inhibited anti-CD3/anti-CD28 mAbs, PHA or alloantigen-induced T cell proliferation without obvious cytotoxicity. Sis-25 was a highly selective inhibitor of GSK3-β and inhibited the mTOR/p70S6K pathway but not the PI3K/Akt, p38 MAPK/ERK 1/2 and JAK3/STAT5 pathways. Furthermore, Sis-25 significantly inhibited IFN-γ, IL-6 and IL-17 expression but not IL-10 expression in activated T cells. Finally, Sis-25 treatment mitigated the DNFB-induced DTH reaction and ameliorated imiquimod-induced dermatitis. In summary, Sis-25 exerted significant immunosuppressive activity by targeting GSK3β in vitro and in vivo. Sis-25 may guide the design of new drugs for more effective and safer treatments of autoimmune diseases and provide new insight into developing utilizations of Isodon scoparius.

Keywords: GSK3β inhibitor; Immunosuppressive effect; Sis-25; T cell proliferation.

MeSH terms

  • Cell Proliferation
  • Cyclobutanes* / pharmacology
  • Dermatitis*
  • Glycogen Synthase Kinase 3
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Imiquimod
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use
  • Phosphatidylinositol 3-Kinases / metabolism

Substances

  • Cyclobutanes
  • Immunosuppressive Agents
  • Glycogen Synthase Kinase 3 beta
  • Glycogen Synthase Kinase 3
  • Imiquimod